Drug Type Small molecule drug |
Synonyms Esflurbiprofen (JAN), Flurbiprofen, (s)-, Mentha Oil + [9] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2015), |
Regulation- |
Molecular FormulaC15H13FO2 |
InChIKeySYTBZMRGLBWNTM-JTQLQIEISA-N |
CAS Registry51543-39-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis | JP | 28 Sep 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Athletic Injuries | Phase 2 | DE | 20 May 2021 | |
Contusions | Phase 2 | DE | 20 May 2021 | |
Soft Tissue Injuries | Phase 2 | DE | 20 May 2021 | |
Sprains and Strains | Phase 2 | DE | 20 May 2021 | |
Acute Pain | Phase 2 | US | 01 Jul 2016 | |
Ankle Injuries | Phase 2 | US | 01 Jul 2016 |
Phase 2 | 200 | (Active Arm) | lpavvhwqnl(ttrdkyizrf) = rzdcmducvx cyjksmfvak (wfllvozaxi, tszeqkotlu - wuyqwxazbs) View more | - | 28 Sep 2023 | ||
(Control Drug) | lpavvhwqnl(ttrdkyizrf) = uxafqwqmuv cyjksmfvak (wfllvozaxi, bmixqrakqo - degfvkgsib) View more |